BCV
EDSA icon

Banque Cantonale Vaudoise’s Edesa Biotech EDSA Stock Holding History

Banque Cantonale Vaudoise’s Portfolio EDSA Stock Details EDSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
3
– – ﹤0.01% 888
2025
Q4 		$0 Buy
+3
New +$6 ﹤0.01% 838

Other funds holding EDSA

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

Banque Cantonale Vaudoise's EDSA Position: Q1 2026 in Review

Banque Cantonale Vaudoise held its Edesa Biotech (EDSA) position steady in Q1 2026 at 3 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #888.

Banque Cantonale Vaudoise first reported a position in EDSA in Q4 2025 and has held it in 2 quarters since. 28 funds tracked by Wall St. Rank hold EDSA as of Q1 2026.

  • Banque Cantonale Vaudoise held 3 shares of Edesa Biotech worth $0 as of Q1 2026.
  • Banque Cantonale Vaudoise left its Edesa Biotech share count unchanged in Q1 2026.
  • Edesa Biotech made up ﹤0.01% of Banque Cantonale Vaudoise's portfolio in Q1 2026, its #888 holding.
  • Banque Cantonale Vaudoise first reported a position in Edesa Biotech in Q4 2025 and has held it in 2 quarters since.
  • 28 funds tracked by Wall St. Rank held Edesa Biotech as of Q1 2026.

Based on Banque Cantonale Vaudoise's 13F filing for Q1 2026, filed 20 Apr 2026.